BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28771778)

  • 1. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
    Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
    Queiro R; Brandy A; Rosado MC; Lorenzo A; Coto P; Carriles C; Alperi M; Ballina J
    J Clin Rheumatol; 2018 Oct; 24(7):381-384. PubMed ID: 29509560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
    Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
    Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
    Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
    Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
    Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
    Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab in psoriatic arthritis: need for studies from real-world evidence.
    Queiro R; Coto-Segura P
    Expert Opin Biol Ther; 2018 Sep; 18(9):931-935. PubMed ID: 30044656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
    Asahina A; Umezawa Y; Yanaba K; Nakagawa H
    J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
    Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
    Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
    Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective is ustekinumab in controlling psoriatic arthritis?
    Bonifati C; Graceffa D
    Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].
    Michel M; Reguiai Z; Fauconier M; Brochot P; Eschard JP; Salmon JH
    Therapie; 2016 Jun; 71(3):281-6. PubMed ID: 27235651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
    Bayaraa B; Imafuku S
    J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of ustekinumab in the treatment of psoriatic arthritis.
    Roberts J; O'Rielly DD; Rahman P
    Immunotherapy; 2018 Apr; 10(5):361-372. PubMed ID: 29439608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.
    Tillett W; Ogdie A; Passey A; Gorecki P
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36650006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
    Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
    Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.